Cardiol Therapeutics Closes $14.85M Bought Deal Financing at Premium, Including Full Over-Allotment
CRDL sits 34% above its 52-week low of $0.771.
Summary
Cardiol Therapeutics has successfully closed its previously announced bought deal financing, raising $14.85 million, including the full exercise of the over-allotment option, with units priced at a premium to the current market.
Key Events · Financing and Capital Events · CRDL
-
Financing Closed
Cardiol Therapeutics announced the closing of its bought deal financing, raising gross proceeds of $14.85 million.
-
Over-Allotment Exercised
The underwriter fully exercised the over-allotment option, increasing the total proceeds from the initial $13.5 million.
-
Premium Pricing
Units were sold at $1.30, which is a premium to the current stock price of $1.03, with warrants exercisable at $1.75.
-
Capital for Development
Proceeds will fund research, clinical development programs, and general corporate purposes, including the ongoing Phase III MAVERIC trial.
Analysis · CRDL · Life Sciences
This filing confirms the successful completion of a significant capital raise for Cardiol Therapeutics, securing $14.85 million in gross proceeds. The offering was priced at $1.30 per unit, which is a notable premium to the company's current stock price of $1.03. The full exercise of the over-allotment option indicates strong investor demand. While dilutive, this financing provides essential capital to advance the company's research and clinical development programs, including the pivotal Phase III MAVERIC trial, and strengthens its balance sheet. The premium pricing suggests institutional confidence in the company's prospects.
At the time of this filing, CRDL was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $104M. The 52-week trading range was $0.77 to $1.59. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.